Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up

Adjuvant chemotherapy of gastric cancer after curative resection is still subject to discussion. In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-F...

Descripción completa

Detalles Bibliográficos
Autores principales: Neri, B, Cini, G, Andreoli, F, Boffi, B, Francesconi, D, Mazzanti, R, Medi, F, Mercatelli, A, Romano, S, Siliani, L, Tarquini, R, Moretti, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363834/
https://www.ncbi.nlm.nih.gov/pubmed/11286464
http://dx.doi.org/10.1054/bjoc.2000.1472
Descripción
Sumario:Adjuvant chemotherapy of gastric cancer after curative resection is still subject to discussion. In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-FU) on days 1–3 every 3 weeks for 7 months, whereas the remaining 68 did not. After a follow-up period of 5 years, 21 of the 69 treated patients (30%) and nine controls (13%) were still alive; median survival time was 18 months for the controls and 31 months for the patients treated with adjuvant chemotherapy (P< 0.01). © 2001 Cancer Research Campaign http://www.bjcancer.com

Ejemplares similares